The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Germany warns vaccinations alone will not contain COVID-19 third wave

Fri, 19th Mar 2021 12:41

* Spahn says doctors will now be more informed of risks

* Merkel to discuss speeding up rollout with state leaders

* Spahn says would favour supply deal for Russia's Sputnik V
(Adds details)

BERLIN, March 19 (Reuters) - Germany's health minister
warned on Friday there was not enough vaccine in Europe to
contain the COVID-19 third wave, as the country sought to get
its rollout back on track following a three-day pause in using
the AstraZeneca shot.

Case numbers have been rising in Germany, driven by an
easing of restrictions in recent weeks just as a more
transmissible variant of the virus has spread, underlining the
need to accelerate vaccinations to protect the vulnerable.

Health Minister Jens Spahn defended the suspension, which
was lifted on Thursday after European Union regulators said the
benefits outweighed the risk, as providing
transparency.

"We can reintroduce AstraZeneca but prudently with informed
doctors and appropriately educated citizens," he said in a
weekly news conference.

But he warned that vaccinations alone would not be able to
contain the third wave as there are not enough doses, and said
restrictions that were lifted may have to be reimposed to
contain the spread of the virus.

"The rising case numbers may mean that we cannot take
further opening steps in the weeks to come. On the contrary, we
may even have to take steps backwards," Spahn said.

State leaders are also due to discuss with Chancellor Angela
Merkel later on Friday ways to speed up the vaccination
campaign, among other by allowing family doctors to start
administering doses at their surgeries.

The suspension was the latest hurdle in Germany's
vaccination campaign, which has been plagued by delivery delays
and news reports of side-effects. As of Friday, just 8.5% of the
population had received a first shot, far behind other countries
like the United States and Britain.

German state leaders said they were ready to quickly catch
up on lost time. In Berlin, anyone who was due to receive an
AstraZeneca shot earlier in the week can turn up at vaccination
centres this weekend without an appointment.

YOUNGER WOMEN

Meanwhile, the premier of the southwestern German state of
Baden-Wuerttemberg, Winfried Kretschmann, 72, is due to receive
an AstraZeneca vaccination on Friday, in a move to shore up
confidence.

But Bodo Ramelow, the premier of Thuringia in eastern
Germany, said he would not advise his wife, who needs to use
blood thinners due to a risk of thrombosis, to get the
AstraZeneca shot although he would do so himself.

Karl Lauterbach, the main health expert of the SPD, Merkel's
junior coalition partner, said it was important to not create
the impression that the AstraZeneca vaccine was not suitable for
younger women.

In Germany, eight people were diagnosed with cerebral venous
sinus thrombosis (CVST) within about two weeks of being
vaccinated. They were among the 1.6 million recipients of the
shot as of Wednesday, with CVST cases higher among women.

Lauterbach said the higher incidence could be due to the
fact that younger women work in the health sector or in
kindergartens, groups that have received the AstraZeneca vaccine
in higher numbers.

Spahn said he hoped vaccinations could take place in
doctors' practices from April 19 at the latest, but warned that
supply would remain restricted.

Germany expects to receive 15 million doses of the
AstraZeneca vaccine in the second quarter, a few million fewer
than initially expected, he said.

Spahn also spoke out in favour of signing a supply deal for
the Russian Sputnik V vaccine for COVID-19, but said there
needed to be greater clarity on the quantities available.

(Reporting by Caroline Copley; Editing by Maria Sheahan and
Paul Simao)

More News
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.